1. Home
  2. ONC vs XYL Comparison

ONC vs XYL Comparison

Compare ONC & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • XYL
  • Stock Information
  • Founded
  • ONC 2010
  • XYL 2011
  • Country
  • ONC Switzerland
  • XYL United States
  • Employees
  • ONC N/A
  • XYL N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • XYL Fluid Controls
  • Sector
  • ONC Health Care
  • XYL Industrials
  • Exchange
  • ONC Nasdaq
  • XYL Nasdaq
  • Market Cap
  • ONC 37.3B
  • XYL 34.2B
  • IPO Year
  • ONC N/A
  • XYL N/A
  • Fundamental
  • Price
  • ONC $342.50
  • XYL $149.49
  • Analyst Decision
  • ONC Strong Buy
  • XYL Buy
  • Analyst Count
  • ONC 10
  • XYL 10
  • Target Price
  • ONC $340.70
  • XYL $152.33
  • AVG Volume (30 Days)
  • ONC 297.4K
  • XYL 1.3M
  • Earning Date
  • ONC 11-11-2025
  • XYL 10-28-2025
  • Dividend Yield
  • ONC N/A
  • XYL 1.07%
  • EPS Growth
  • ONC N/A
  • XYL 21.62
  • EPS
  • ONC N/A
  • XYL 3.84
  • Revenue
  • ONC $4,562,002,000.00
  • XYL $8,730,000,000.00
  • Revenue This Year
  • ONC $896.81
  • XYL $5.56
  • Revenue Next Year
  • ONC N/A
  • XYL $5.23
  • P/E Ratio
  • ONC N/A
  • XYL $39.03
  • Revenue Growth
  • ONC 47.33
  • XYL 3.98
  • 52 Week Low
  • ONC $170.99
  • XYL $100.48
  • 52 Week High
  • ONC $355.30
  • XYL $150.98
  • Technical
  • Relative Strength Index (RSI)
  • ONC 57.00
  • XYL 71.87
  • Support Level
  • ONC $334.53
  • XYL $147.42
  • Resistance Level
  • ONC $355.30
  • XYL $144.31
  • Average True Range (ATR)
  • ONC 7.30
  • XYL 2.43
  • MACD
  • ONC 0.00
  • XYL 0.78
  • Stochastic Oscillator
  • ONC 61.75
  • XYL 88.10

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

About XYL Xylem Inc. New

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.

Share on Social Networks: